Free Trial
NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis

Alnylam Pharmaceuticals logo
$320.52 -0.01 (0.00%)
Closing price 07/21/2025 04:00 PM Eastern
Extended Trading
$319.70 -0.82 (-0.26%)
As of 09:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)

Key Stats

Today's Range
$320.26
$328.70
50-Day Range
$266.86
$331.94
52-Week Range
$205.87
$333.70
Volume
744,525 shs
Average Volume
848,565 shs
Market Capitalization
$41.79 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$347.75
Consensus Rating
Moderate Buy

Company Overview

Alnylam Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

ALNY MarketRank™: 

Alnylam Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 192nd out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 22 buy ratings, 3 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Alnylam Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Alnylam Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($1.70) to $0.89 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alnylam Pharmaceuticals is -153.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alnylam Pharmaceuticals is -153.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Alnylam Pharmaceuticals has a P/B Ratio of 616.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Alnylam Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    2.59% of the float of Alnylam Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alnylam Pharmaceuticals has recently decreased by 1.48%, indicating that investor sentiment is improving.
  • Dividend Yield

    Alnylam Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Alnylam Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.59% of the float of Alnylam Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Alnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alnylam Pharmaceuticals has recently decreased by 1.48%, indicating that investor sentiment is improving.
  • News Sentiment

    Alnylam Pharmaceuticals has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 36 news articles for Alnylam Pharmaceuticals this week, compared to 16 articles on an average week.
  • Search Interest

    Only 9 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,535,782.00 in company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alnylam Pharmaceuticals' insider trading history.
Receive ALNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALNY Stock News Headlines

Miss This Window And You Miss Everything
There’s a moment in every crypto cycle when everything just clicks — and that moment is now. This is the phase when momentum builds, news turns bullish, and markets ignite. Inside The Crypto Code Workshop, you’ll get the roadmap to ride this wave — and $10 in free Bitcoin just for showing up.
Leerink Partnrs Brokers Reduce Earnings Estimates for ALNY
See More Headlines

ALNY Stock Analysis - Frequently Asked Questions

Alnylam Pharmaceuticals' stock was trading at $235.31 at the start of the year. Since then, ALNY stock has increased by 36.2% and is now trading at $320.52.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings results on Thursday, May, 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.07. The business's quarterly revenue was up 20.2% on a year-over-year basis.
Read the conference call transcript
.

Alnylam Pharmaceuticals' top institutional investors include Robeco Institutional Asset Management B.V. (0.07%), Swedbank AB (0.05%), U.S. Capital Wealth Advisors LLC (0.04%) and Public Employees Retirement System of Ohio (0.03%). Insiders that own company stock include Yvonne Greenstreet, Jeffrey V Poulton, Akshay Vaishnaw, Michael W Bonney, Tolga Tanguler, Kevin Joseph Fitzgerald, Pushkal Garg, Amy W Schulman, Dennis A Ausiello, David E I Pyott, Phillip A Sharp and Indrani Lall Franchini.
View institutional ownership trends
.

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alnylam Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and The RMR Group (RMR).

Company Calendar

Last Earnings
5/01/2025
Today
7/22/2025
Next Earnings (Confirmed)
7/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALNY
CIK
1178670
Employees
2,230
Year Founded
2002

Price Target and Rating

High Price Target
$500.00
Low Price Target
$220.00
Potential Upside/Downside
+8.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
26 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$278.16 million
Net Margins
-11.49%
Pretax Margin
-15.14%
Return on Equity
-510.31%
Return on Assets
-6.48%

Debt

Debt-to-Equity Ratio
8.88
Current Ratio
3.04
Quick Ratio
2.98

Sales & Book Value

Annual Sales
$2.35 billion
Price / Sales
17.80
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.52 per share
Price / Book
616.38

Miscellaneous

Outstanding Shares
130,388,000
Free Float
128,823,000
Market Cap
$41.79 billion
Optionable
Optionable
Beta
0.23

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:ALNY) was last updated on 7/22/2025 by MarketBeat.com Staff
From Our Partners